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Abstract
Background: Quality of life (QoL) is multi-dimensional concept of an individual’ general well-being status in
relation to their value, environment, cultural and social context in which they live. This study aimed to
quantitatively synthesise available evidence on the association between QoL and mortality in the general
population.
Methods: An electronic search was conducted using three bibliographic databases, MEDLINE, EMBASE and
PsycINFO. Inclusion criteria were studies that assessed QoL using standardized tools and examined mortality risk in
a non-patient population. Qualitative data synthesis and meta-analyses using a random-effects model were
performed.
Results: Of 4184 articles identified, 47 were eligible for inclusion, involving approximately 1,200,000 participants.
Studies were highly heterogeneous in terms of QoL measures, population characteristics and data analysis. In total,
43 studies (91.5%) reported that better QoL was associated with lower mortality risk. The results of four meta-
analyses indicated that higher health-related QoL (HRQoL) is associated with lower mortality risk, which was
consistent for overall HRQoL (HR 0.633, 95% CI: 0.514 to 0.780), physical function (HR 0.987, 95% CI: 0.982 to 0.992),
physical component score (OR 0.950, 95% CI: 0.935 to 0.965), and mental component score (OR 0.980, 95% CI: 0.969
to 0.992).
Conclusion: These findings provide evidence that better QoL/HRQoL was associated with lower mortality risk. The
utility of these measures in predicting mortality risk indicates that they should be considered further as potential
screening tools in general clinical practice, beyond the traditional objective measures such as body mass index and
the results of laboratory tests.
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Background
Quality of life (QoL) is a multi-dimensional concept of
an individual’s general well-being status in relation to the
value, environment, cultural and social context in which
they live [1]. Since QoL measures outcomes beyond bio-
logical functioning and morbidity [2], it is recognised as
an important measure of overall [1]. The origin of the
term QoL dates back to the early 1970s, as a measure of
wellness with linkage to health status like diseases or dis-
ability [3, 4]. Since then, interest in QoL has increased
considerably [5]. As life expectancy increases, more em-
phasis has been placed on the importance of better QoL,
and the maintenance of good health for as long as possible
[6–9]. Indeed, global leading health organizations have
emphasized the importance of QoL and well-being as a
goal across all life stages [10–12].
Moreover, QoL has increasingly been used in the wider
context to monitor the efficacy of health services (e.g. pa-
tient reported outcome measures, PROMs), to assess
intervention outcomes, and as an indicator of unmet
needs [13–15]. Several studies have reported that QoL is
negatively associated with rehospitalization and death in
patients with diseases such as coronary disease [16, 17],
and pulmonary diseases [18]. Further, QoL is also predict-
ive of overall survival in patients affected by cancer,
chronic kidney disease or after coronary bypass graft sur-
gery [19–22]. In recent years, an increasing number of
studies have investigated whether QoL is also a predictor
of mortality risk in the general population [23–27].
To date, there has been only one pooled analysis of
eight heterogeneous-Finnish cohorts. That study of 3153
older adults, focused exclusively on the prognostic value
of the validated 15-dimentional (15D) health-related
QoL (HRQoL) measures [28] for predicting all-cause
mortality [29]. However, there has been no systematic
review investigating the association between QoL mea-
sured by different instruments and all-cause mortality in
population-based samples which could be used to moni-
tor health changes in the general population. A broad
and comprehensive systematic review of the prognostic
value of QoL for all-cause mortality prediction is needed
to determine the utility of this QoL measure as a poten-
tial screening tool in general clinical practice. Therefore,
this systematic review and meta-analysis was conducted
with the aim of determining whether QoL is predictive
of mortality in the general population which includes in-
dividuals with or without a range of health conditions.
Methods
Search methods
This systematic review and meta-analysis were con-
ducted in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [30]. The protocol for this review was
registered with the International Prospective Register of
Ongoing Systematic Reviews (PROSPERO) [31], under
the registration number: CRD42019139994 [32]. The
electronic bibliographic databases, MEDLINE, EMBASE
and PsycINFO (through OVID) were searched from
database inception until June 21, 2019. The search strat-
egy was developed in consultation with a Senior Medical
Librarian. The MeSH terms and key-words were devel-
oped for MEDLINE (through OVID) and were translated
to EMBASE and PsycINFO using the OVID platform
(See Supplementary Tables S1-S3, Additional File 1).
When the full text of an article was not available, all at-
tempts were made to obtain it by contacting the authors
directly. To identify further potentially relevant studies,
another search was also developed with those specific
QoL / HRQoL measures which were found in this re-
view (See Supplementary Table S4, Additional File 1).
Additionally, the bibliography lists of the included arti-
cles were also hand searched.
Inclusion and exclusion criteria
Articles were included if they: (a) involved adults aged
18 years and older; (b) were general population-based
samples with or without a range of health conditions; (c)
assessed mortality from any cause or cause-specific mor-
tality using a longitudinal design; and (d) included a
QoL / HRQoL measure using a standard tool. QoL, the
general well-being of individuals, consists of a range of
contexts – health, education, employment, wealth, polit-
ics and the environment [33]. HRQoL, the self-perceived
health status, includes physical, mental, emotional, and
social domains [33]. We excluded papers not written in
English, reviews, or studies including only specific
groups of patients (e.g. patients on dialysis, those with
fractures, after surgery, or individuals with a terminal
illness).
Study selection
The screening of articles for eligibility according to title
and abstract was undertaken independently by two re-
viewers (AZZP and HC). All relevant full-text articles
were independently reviewed by two reviewers (AZZP
and HC) for eligibility against inclusion criteria. The
inter-coder reliability among two reviewers (AZZP and
HC) was 98%. Discrepancies and disagreements between
two reviewers (AZZP and HC) were resolved through
discussion with a third reviewer (JR). The screening
process was undertaken using Covidence online software
[34] and EndNote X9 software.
Data extraction
A standard data extraction form was used which
included the following fields – title, authors, year of pub-
lication, setting/country, name of the study and design,
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sample size, follow-up period, participant characteristics
(age and sex), specific QoL measure, cause of death (if
available), and results (risk estimates including 95% con-
fidence intervals, CI) which were standardized in term of
1-unit increase or 1-SD increase for continuous risk esti-
mate, or high vs. low for categorical risk estimates. The
first reviewer (AZZP) completed the data extraction
form and a second reviewer (HC) verified the extracted
information. All efforts were made to contact authors
when there was missing information.
Quality appraisal
The quality of included studies was appraised using ‘the
Newcastle – Ottawa Quality Assessment Scale (NOS)’
[35]. The NOS includes eight items, categorized into
three dimensions (a) Selection, (b) Comparability, and
(c) Outcome. The NOS scale uses a star system to evalu-
ate the quality of each study, and they can be accredited
a maximum of one star for each item within the Selec-
tion and Outcome dimension and two stars for the
Comparability item. When considering the comparability
of each study, a star was provided for studies which con-
trolled for relevant covariates – age, sex (where appro-
priate), socioeconomic status or proxy (including
socioeconomic position, education level or income), and
some measure of co-morbidity (for example a specific
health condition). An additional star was given for stud-
ies which considered other factors associated with QoL
and mortality, including clinical measures, BMI, or life-
style factors (i.e. smoking, alcohol, physical activity). The
range of NOS scoring was from 0 to 9 stars, with higher
scores indicating less susceptibility to bias. The meth-
odological quality of included studies was rated by one
reviewer (AZZP) and verified by a second reviewer (HC).
Disagreements were resolved through discussion with a
third reviewer (JR).
Data synthesis
The clinical and methodical heterogeneity of the studies
was examined, in particular considering the measure of
QoL used, and the effect estimates reported (Hazard Ra-
tio (HR), Relative Risk (RR) or Odds Ratio (OR)). Where
studies were considered too methodically heterogeneous
to enable pooling, the results were summarized quantita-
tively in tables according to related categories with risk
estimates; and 95% CIs.
Meta-analysis
A meta-analysis was performed when there was a suffi-
cient number of studies (four or more) which used the
same domain of QoL measure and equivalent effect
estimate parameters. In the present study, four meta-
analyses were conducted for a pooled risk estimate of
studies using (a) physical component score (PCS) of 36-
item Short Form (SF-36) and OR / RR; (b) physical
function domain of SF-36 and HR; (c) mental
component score (MCS) of SF-36 and OR / RR; and (d)
the 15-dimensional measure (15D) and HR. A
DerSimonian-Laird random-effects model was chosen
given heterogeneity in the studies in terms of population
characteristics and varying health status. When more
than one risk estimate was reported in the study, the
fully adjusted/final regression model was included. In
addition, when the included studies from the same
cohorts with the same follow-up were eligible for meta-
analysis, only one study with larger sample size was
chosen for meta-analysis. Effect estimates were standard-
ized where possible, so all values corresponded to a 1-
unit increase in SF-36 or a 1-SD increase in 15D (single
index number). A pooled risk estimates of less than one
indicates a decreased risk of mortality with higher QoL.
Statistical heterogeneity was evaluated by using the I2
statistic, and the results were interpreted based on the
Cochrane guidelines (0–40% = no heterogeneity; 30–
60% =moderate heterogeneity; 50–90% = substantial
heterogeneity; and 75–100% = considerable heterogen-
eity) [36]. In addition, when the I2 statistic showed con-
siderable heterogeneity (≥ 75%), the influence of
individual studies on the pooled risk estimate was
assessed using the metaninf command of STATA. Fun-
nel plots and Egger’s test were used to assess publication
bias. Data analysis was undertaken using STATA statis-
tical software, version 15.0 (StataCorpLP, College Sta-
tion, TX, USA).
Results
Search result
A total of 4175 articles were identified from the system-
atic database search, and six additional articles were
found via searching the reference list of included articles
(Fig. 1). After removing duplicates, 3140 records
remained for review. After title and abstract screening,
3058 articles were excluded and the full-text of the
remaining 82 articles were evaluated for eligibility. A
total of forty-four (44) articles met all inclusion criteria.
Excluded articles with reasons for exclusion are pre-
sented in Supplementary Table S5, Additional File 1.
Moreover, three articles from additional search were also
added in this review. Therefore, a total of forty-seven
(47) articles were included in this systematic review.
Description of included studies
Table 1 presents the characteristics of the 47 included
studies. The earliest study was published in 1993 while
the remaining included articles were published between
2002 and 2019, with 28% published in the past 5 years.
All studies except the retrospective cohort study of Ul-
Haq et al., [75] were prospective cohort studies. The
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included studies were conducted in USA (34%), UK
(9%), Australia (6%), Canada (6%), Spain (6%), Taiwan
(6%), Belgium (4%), Finland (4%), Scotland (4%),
Sweden (4%), Bangladesh (2%), China (2%), Germany
(2%), South Korea (2%), Italy (2%), Norway (2%), and
South Africa (2%). The sample sizes of the included
studies ranged from 171 [41] to 559,985 [40]; 14
studies had a sample size of less than 1000, 17 stud-
ies between 1000 and 10,000, 13 studies between 10,
000 and 100,000, and the remaining three studies [38,
40, 53] has a sample size of more than 100,000 par-
ticipants. Five studies included only males [41, 42, 54,
71, 73] and three studies only females [56, 59, 74].
The remaining 39 studies recruited between 3 to 78%
of women. The follow-up periods of the studies var-
ied between 9 months [72] and 18 years [73].
This review included a variety of different QoL mea-
sures and half of the included studies (24 studies) mea-
sured QoL using the Short Form 36 (SF-36) (Tables 1
and 2). Of the 47 articles included in this review (Table
1), some studies involved the same cohorts and, in sev-
eral cases, likely the same participants. Subsequent pub-
lications often reported effect estimates over different
lengths of follow-up or using different QoL tools. Two
published articles of De Buyser et al. reported the results
of the same population-based cohort study [41, 42],
three published articles by De Salvo et al. and Fan et al.
were from the same study and included participants en-
rolled in the Veterans Affairs Ambulatory Care Quality
Improvement Project [24, 43, 47], two published studies
of Mold et al. and Lawler et al. used the same
community-dwelling cohort [57, 61], two published
Fig. 1 Flow Diagram of Review Process
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studies of Higueras-Fresnillo et al. and Otero-Rodriguez
et al. were from the same Spanish cohort [52, 67], two
published studies of Feeny et al. and Kaplan et al. were
from the same Canadian cohort [48, 55]; and Myint
et al. published three articles [26, 64, 65] with different
perspectives on the same population-based study. Add-
itionally, Liira et al.’s study [29], included eight individ-
ual cohorts, however, only five of the cohorts met the
inclusion criteria for this current systematic review, and
thus are shown in Table 1.
Risk of Bias assessment
The methodological quality of included studies based on
NOS ranged between five and nine stars. Among the
included studies, seven were of high methodological
quality, with nine stars. Across the ten studies with less
than seven stars, they were scored most poorly on the
items assessing how representative the cohort was in rela-
tion to the overall population being sampled and whether
they adjusted for potential confounding factors in their ana-
lysis (See Supplementary Table S6-S7, Additional File 1).
Qualitative synthesis
Of the total 47 included studies, 43 (91.5%) studies re-
ported for at least one of the domains examined, that bet-
ter QOL was associated with lower mortality risk (Table
1). Of 33 studies which assessed physical HRQoL (nine ex-
clusively assessed physical HRQoL), 30 studies (91%) re-
ported better HRQoL was associated with lower mortality
risk. Among the 23 studies which examined mental
HRQoL (one exclusively assessed MCS), 13 studies (57%)
reported that higher mental HRQoL was associated with
decreased mortality risk (Table 1). The five studies [49, 52,
57, 59, 76] that measured HRQoL using SF-36 or SF-20
reported not only the physical functioning and mental
health domains, but also general health perception, bodily
pain, vitality, and social functioning. The findings were
generally consistent in general health perception and
social functioning; and it was reported that better level of
general health perception and social functioning was asso-
ciated with decreased mortality risk (Table 1).
The mortality risk estimates of the studies which were
not included in the meta-analyses are shown in Tables 3,
4 and 5. The 18 out of 20 studies which measured the
PCS using the SF-36 or SF-12 or the physical function-
ing subscale using SF-36, RAND-36, or SF-20 reported
these to be a predictor of mortality risk, with better
physical health being associated with lower mortality risk
(Table 3). Nine out of 16 studies which assessed the
MCS or mental health subscale using SF-36 or SF-12,
showed that better mental health was associated with
lower mortality risk (Table 4). The 12 out of the 15 stud-
ies that measured the association between QoL and
mortality risk, found that higher QoL scores were associ-
ated with lower mortality risk (Table 5).
Meta-analyses
Four studies including 53,642 participants [23, 24, 60,
70] measured QoL using the SF-36 and examined the as-
sociation between the PCS and all-cause mortality and
provided estimates from logistic regression analysis (OR
or RR). With an average 1.8-year follow-up, one unit in-
crease in the SF-36 PCS was associated with a 5% de-
crease in all-cause mortality (pooled OR/RR = 0.950; 95%
CI: 0.935 to 0.965; P-value < 0.001). There was substan-
tial heterogeneity between studies (I2 = 82.1%; P-value =
0.001) (Fig. 2-a).
Table 2 Quality of life scale included in the systematic review
QoL Scale Study
Short Form Health Survey scales SF-36, SF-20, SF-12, RAND-36 Study [23, 24, 27, 37, 40–43, 45–47,
49–52, 56–62, 64, 65, 67, 68, 70, 71, 74–76
]
World Health Organization questionnaires WHOQOL, WHOQOL-BREF Study [25, 54, 63, 69]
Centre for Diseases Control and Prevention Health Related
Quality of Life scale
CDC HRQOL Study [38, 44]
Six Dimensions Short Form Scale SF-6D Study [26, 53]
Euro Quality of Life scale EQ-5D Study [39, 53]
Health Utilities Index 3 HUI3 Study [48, 55]
Psychological General Well-Being Index PGWB Study [66]
15-dimensional index 15D Study [29]
Goteborg Quality of Life Instrument Goteborg QoL Study [73]
Lancashire Quality of Life Profile-Residential incorporated
the Spitzer Uniscale
LQOLP-Residential incorporated the
Spitzer Uniscale
Study [72]
Chinese 35-Item Quality of Life Instrument Chinese QOL-35 Study [77]
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Six studies including 22,570 participants [42, 46, 57,
59, 68, 76] measured QoL using the SF-36 and investi-
gated the association between the physical functioning
and all-cause mortality using time-to-event survival ana-
lysis. With an average 8.7-year follow-up, one unit in-
crease in the SF-36 PF was associated with a 1.3%
decrease in time to death (pooled HR = 0.987; 95%CI:
0.982 to 0.992; P-value < 0.001). There was substantial
heterogeneity between studies (I2 = 83.8%; P-value <
0.001) (Fig. 2-b).
Four studies including 53,642 participants [23, 24, 60,
70] measured QoL using the SF-36 and examined the as-
sociation between the MCS and all-cause mortality re-
ported estimates on logistic regression analysis (OR or
RR). With an average 1.8-year follow-up, one unit in-
crease in the SF-36 MCS was associated with a 2%
Table 3 Physical component score / physical functioning as predictors of all-cause mortality
Author (Year) Comparison Effect estimate (95% CI)
SF – 36 Physical Component Score (continuous)
Chwastiak et al. 2010 [40] HR, 1-unit increase 0.97 (0.96–0.98)
DeSalvo et al. 2005 [43] AUC 0.73 (0.71–0.75)
Fan et al. 2006 [47] AUC 0.721 (0.708–0.733)
Otero-Rodriguez et al. 2010f [67] HR, 1-unit increase 0.952 (0.935–0.969)
SF-36 Physical Function Scale (continuous)
De Buyser et al. 2016 a,f [41] HR, 1-unit increase 1.01 (0.99–1.02)
Mold et al. 2008 b [61] HR, 1-unit increase 0.98 (0.97–0.99)
RAND-36 Physical Function Scale (continuous)
Bjorkman et al. 2019 [37] HR, 1-unit increase 0.988 (0.979–0.997)
SF – 36 Physical Component Score (categorised)
Forsyth et al. 2018f [27] HR, High vs. Low 0.48 (0.18–1.20) e
Han et al. 2009 [50] HR, Tertile 3 High vs. Tertile 1Low 0.35 (0.19–0.64)
Higueras-Fresnillo et al.2018f [52] HR, Good vs. Poor 0.74 (0.65–0.85)
Myint et al. 2006f [64] RR, Quintile 5 Highest vs. Quintile 1 Lowest 0.47 (0.33–0.65) Men
0.41 (0.27–0.64) Women
St. John et al. 2018f [71] RR, High vs. Low 0.50 (0.38–0.64)
SF – 36 Physical Functioning (categorised)
Lee et al. 2012f [58] HR, Highest vs. Lowest 0.29 (0.19–0.45)
SF – 36 Change in Physical Component Score (categorised)
Kroenke et al. 2008 [56] RR, Severe Decline vs. No Change 3.32 (2.45–4.50)
RR, Improvement vs. No Change 0.72 (0.56–0.91)
SF – 20 Physical Function Scale (continuous)
Franks et al. 2003f [49] HR, 1-point increase0.995 (0.992–0.997) 0.995 (0.992–0.997)
SF – 20 Physical Function Scale (categorised)
Tice et al. 2006 [74] HR, Highest vs. Lowest 0.70 (0.60–0.90)
SF – 12 Physical Component Score (categorised)
Dorr et al. 2006f [45] OR, Highest Quartile vs. Lowest Quartile 0.16
Haring et al. 2011f [51] HR, Highest Quartile vs. Lowest Quartile 0.56 (0.42–0.75) c
0.63 (0.47–0.84) d
Munoz et al. 2011 [62] HR, 3rd Tertile vs. 1st Tertile 0.58 (0.39–0.87)
UI-Haq et al. 2014f [75] HR, Best Quintile vs. Worst Quintile 0.36 (0.22–0.57)
aDe Buyser et al. (2016) and De Buyser et al. (2013) were from the same study. De Buyser et al. (2013) was included in meta-analysis
bLawler et al. (2013) and Mold et al. (2008) were from the same study. Lawler et al. (2013) was included in meta-analysis
cbehavioural factors adjusted
dcomorbidities adjusted
e CI is 99% CI
fwhere studies report reverse association or risk estimate per more than 1-unit increase, the risk estimates were standardised per 1-unit increase or 1-SD increase
or high vs. low for the purpose of consistency across the table
AUC Area under curve
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decrease in all-cause mortality (pooled OR/RR = 0.980;
95% CI: 0.969 to 0.992; P-value = 0.001). There was sub-
stantial heterogeneity between studies (I2 = 75.9%; P-
value = 0.01) (Fig. 2-c).
Given the heterogeneity identified in the three meta-
analyses described above, the influence of individual
studies on the pooled risk estimate was assessed. The re-
moval of no single study affected the association (Sup-
plementary Table S8 – S10, Additional File 1).
Five Finnish individual cohorts of the Liira et al. study
including 2377 [29] measured QoL using the 15D index
and explored its association with all-cause mortality
using time-to-event survival analysis. With an average 2-
year follow-up, one SD (0.14) increase in the 15D index
was associated with a 36.7% decrease in all-cause mortal-
ity (pooled HR = 0.633; 95%CI: 0.514 to 0.780; P-value <
0.001). There was moderate heterogeneity between stud-
ies (I2 = 49.4%; P-value = 0.10) (Fig. 3).
Visual inspection of the funnel plots which were used
to assess for publication bias were presented in the Sup-
plementary Figures S1-S4, Additional File 1. For three of
the four meta-analyses, there was no strong evidence of
publication bias, however for the meta-analysis of MCS,
this test was statistically significant (P = 0.04).
Discussion
This systematic review is the first to investigate the asso-
ciation between QoL and mortality in community-
dwelling individuals with or without health conditions
rather than patients in a hospital or people living in
assisted living. It summarizes the findings from 47 stud-
ies including approximately 1,200,000 individuals aged
predominantly 65 years and older (age range 18–101
years), with 46 studies (98%) conducted in high-income
or upper-middle-income countries. Overall thirteen dif-
ferent instruments were used to assess the association
Table 4 Mental component score / mental health as predictors of all-cause mortality
Author (Year) Comparison Effect estimate (95% CI)
SF – 36 Mental Component Score (continuous)
DeSalvo et al. 2005 [43] AUC 0.68 (0.66–0.70)
Fan et al. 2006 [47] AUC 0.689 (0.675–0.702)
Myint et al. 2007d [65] HR, 1-unit increase 0.987 (0.981–0.993)
Otero-Rodriguez et al. 2010d [67] HR, 1-unit increase 0.990 (0.976–1.006)
SF – 36 Mental Health (continuous)
Leigh et al. 2015 [59] HR, 1-unit increase 1.00 (0.997–1.002)
Williams et al. 2012d [76] HR, 1-point-change 0.999 (0.994–1.004)
SF – 36 Mental Component Score (categorised)
Forsyth et al. 2018d [27] HR, High vs. Low 0.38 (0.16–0.91) c
Han et al. 2009 [50] HR, Tertile 3 High vs. Tertile 1Low 0.39 (0.22–0.70)
Higueras-Fresnillo et al. 2018d [52] HR, Good vs. Poor 0.85 (0.74–0.98)
St. John et al. 2018d [71] RR, High vs. Low 0.55 (0.40–0.76)
SF – 36 Change in Mental Component Score (categorised)
Kroenke et al. 2008 [56] RR, Severe Decline vs. No Change
RR, Improvement vs. No Change
1.86 (1.17–2.97)
0.77 (0.63–0.95)
SF – 20 Physical Function Scale (continuous)
Franks et al. 2003d [49] HR, 1-point increase 1.00 (0.996–1.003)
SF – 12 Mental Component Score (categorised)
Dorr et al. 2006d [45] OR, Highest Quartile vs. Lowest Quartile 0.40
Haring et al. 2011d [51] HR, Highest Quartile vs. Lowest Quartile 0.94 (0.73–1.22) a
1.04 (0.81–1.35) b
Munoz et al. 2011 [62] HR, 3rd Teritle vs. 1st Tertile 0.99 (0.69–1.42)
UI-Haq et al. 2014d [75] HR, Best Quintile vs. Worst Quintile 0.80 (0.61–1.05)
abehavioural factors adjusted
bcomorbidities adjusted
c 99% CI
dwhere studies report reverse association or risk estimate per more than 1-unit increase, the risk estimates were standardised per 1-unit increase or 1-SD increase
or high vs. low for the purpose of consistency across the table
AUC Area under curve
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between QoL or more specifically HRQoL and mortality
risk after 9 months to 18 years of follow-up, with the SF-
36 or its derivatives (RAND-36, SF-20, SF-6D) most
commonly used. Overall, 43 (91.5%) studies of the 47 in-
cluded studies reported for at least one of the domains
examined, that better QoL was associated lower mortal-
ity risk, which was also supported by the results of four
meta-analyses (11 studies, n = 78,589) of PCS, physical
function and MCS domains of the SF-36, and 15D
HRQoL.
Our findings are in line with a previous study that
used pooled analysis [29] of eight heterogenous Finnish
cohorts using the 15D HRQoL measure and included a
wide range of both community-dwelling participants
with or without morbidity, such as cardiovascular dis-
ease, dementia, and hospitalized patients with delirium.
They also found that the 15D HRQoL measure was
associated with two-year survival, with a slightly higher
hazard ratio than that found in our study (HR per 1-
SD = 0.44, 95% CI 0.40 to 0.48) [29]. These differences
may relate to their inclusion of patient groups in
generally poorer health, while our systematic review
focused on the community dwelling population.
Moreover, our findings in the general non-patient
population are also comparable with studies investi-
gating people with specific diseases such as cancer
Table 5 Other QoL measures rather than SF / RAND, as predictor of all-cause mortality
Author (Year) Comparison Effect estimate (95% CI)
Core CDC Healthy Days Measures (HRQOL-4) (General Health) categorised
Brown et al. 2015a [38] HR, Excellent vs. Poor 0.24 (0.21–0.27)
Dominick et al. 2002a [44] RR, Excellent vs. Poor 0.24 (0.17–0.33)
WHO QOL – BREF (Overall)
Kao et al. 2005 [54] RR, 1-point change 0.99 (0.77–1.26)
Murray et al. 2011 [63] HR, 1-tertile increase 0.84 (0.67–1.05)
WHO QOL (Categorised)
Gomez-Olive et al. 2014a [25] HR, Highest vs. Lowest 0.61
Razzaque et al. 2014a [69] RR, Good vs. Bad 0.26 (0.16–0.41) men
0.30 (0.10–0.86) women
Psychological General Well-being (PGWB) (Global Score) continuous
Nilsson et al. 2011a [66] RR, 1-unit change 0.984 (0.969–0.998) men
0.994 (0.978–1.010) women
Lancashire Quality-of-life Profile-Residential (LQOLP-R) incorporated the Spitzer Uniscale
Sutcliffe et al. 2007 [72] HR, increased score 0.9805 (0.9704–0.9907)
Chinese 35-item Quality of Life (QOL-35) categorised
Xie et al. 2014a [77] HR, Upper 50% vs. Lower 50% 0.69 (0.49–1.00)
The Health Utilities Index Mark 3 Version (HUI3) continuous
Feeny et al. 2012 [48] HR, 1-level increase Hearing: 0.18 (0.06–0.57)
Ambulation: 0.10 (0.04–0.23)
Pain: 0.53 (0.29–0.96)
Kaplan et al. 2007 [55] HR, 1-unit increase Overall: 0.61 (0.42–0.89)
The EuroQoL-5 Dimension (EQ-5D) continuous
Cavrini et al. 2012 [39] HR, 1-unit increase 0.42 (0.35–0.50)
The EuroQoL-5 Dimension EQ-5D categorised
Jia et al. 2018a [53] HR, 5th Quintile vs. 1st Quintile 0.45 (0.43–0.49)
Short Form Six Dimension Utility Index (SF-6D) continuous
Myint et al. 2010a [26] HR, 1SD 0.12-point increase 0.74 (0.69–0.79)
Short Form Six Dimension Health Utility Measure (SF-6D) categorised
Jia et al. 2018a [53] HR, 5th Quintile vs. 1st Quintile 0.77 (0.71–0.80)
Goteborg Quality of Life Assessment
Tibblin et al. 1993 [73] Only Health variable was significantly related to mortality (No data available)
awhere studies report reverse association or risk estimate per more than 1-unit increase, the risk estimates were standardised per 1-unit increase or 1-SD increase
or high vs. low for the purpose of consistency across the table
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and chronic kidney disease, which reported QoL to
be a predictor of mortality risk [19–21].
The findings of the present study are also consistent
with those of recent population-based systematic review
which investigated on the association between QoL and
multimorbidity [78]. In their recent study, Makovski
et al. (2019) systematically reviewed the evidence on the
relationship between QoL and multimorbidity. They ob-
served a stronger relationship between the PCS of QoL
and multimorbidity (overall decline in QoL per add-
itional disease = − 4.37, 95%CI − 7.13% to − 1.61% for
WHOQoL-BREF physical domain and − 1.57, 95%CI −
Fig. 2 Forest plot of all-cause mortality risk per one unit increase in a SF-36 PCS, b SF-36 Physical-Functioning, c SF-36 MCS. CI = confidence
interval; FU (yrs) = follow-up in years; N = sample size; OR = odds ratio; RR = relative risk; HR = hazard ratio
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2.70% to − 0.44% for WHOQoL-BREF mental domain)
[78]. These findings also align with the results of the
present study, where the meta-analysis indicated a
stronger effect size for PCS compared to MCS using
the SF-36 tool (pooled OR/RR = 0.950; 95% CI: 0.935
to 0.965 for PCS; and pooled OR/RR = 0.980; 95%CI:
0.969 to 0.992 for MCS). Since physical health is gen-
erally recognised as a strong risk factor for comorbid-
ity, hospitalisations and mortality [79–82], our
findings add further support to the predictive capacity
of physical HRQoL for mortality risk. Like other ob-
jective health measures such as body mass index, gly-
caemia, and blood pressure, these findings highlight
the utility of assessing physical HRQoL in general
clinical practice to help identify individuals at greatest
risk of death [83].
Given the evidence regarding the longitudinal relation-
ship between QoL and mortality risk, the utility of a
QoL tool in general care may improve patient’ health
which in turn would decrease mortality. Furthermore,
mental health issues such as depression or anxiety could
also be identified through QoL measures and this would
enable initiation of early interventions for mental health
which in turn could improve long term QoL of individ-
uals. Hence, the finding of this review can help to in-
crease the efficacy of disease prevention strategies in
older people through identifying individuals at higher
risk for adverse health outcomes in general practice /
primary health settings. Thus, the mortality risk predic-
tion by QoL might not be very relevant to younger
healthy populations although QoL generic measures
were designed to be used across a wide range of popula-
tions [84]. There is a need for further studies however,
in particular to better understand the influence of gen-
der on these associations, and whether differences could
be observed for males and females. Understanding these
specific relationships could help identify which particular
groups are most at risk and enable specific targeting of
interventions to these individuals.
Strengths of the review
Strengths of this systematic review are that it was per-
formed in a rigorous manner, adhering to strict system-
atic review guidelines. The protocol was registered with
the International prospective register of systematic re-
views (PROSPERO), and the review was undertaken in
accordance with the preferred reporting items for sys-
tematic reviews and meta-analyses (PRISMA) statement.
A reproducible and rigorous search strategy using three
electronic databases was used, which helped ensure that
all relevant articles were included. The literature screen-
ing was independently performed by two reviewers, who
were also involved in the process of data extraction and
methodological quality assessment of the included stud-
ies in accordance with NOS. Based on the NOS, all stud-
ies received greater than or equal to five out of nine
stars, which indicates that there was generally a low risk
of bias. Similarly, most studies provided risk estimates
that controlled for important factors including current
health and socio-economic status. Since our review cri-
teria were not limited to articles with the commonly
used QoL (or HRQoL) tools such as the SF-36, this has
increased the generalisability of the findings. Therefore,
this review has a broad and comprehensive perspective,
with results that are rigorous and can be reproduced.
Limitations of the review
Among included articles, large heterogeneity was ob-
served in terms of country-of-origin, participant charac-
teristics, and evaluation of QoL. The majority of the
included articles were conducted in English speaking
counties, and restriction to English language articles as
part of our inclusion criteria, may impact the generalis-
ability of these findings. Since the different QoL
Fig. 3 Forest plot of all-cause mortality risk per one-SD (0.14) increase in 15D index. CI = confidence interval; FU (yrs) = follow-up in years; HR =
hazard ratio; N = sample size
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standard tools examine different aspects [33, 85] and are
not directly comparable, this made comparison of in-
cluded studies in data synthesis difficult. There were also
some differences in the way the data analysis was per-
formed and the results were presented, reporting OR
versus HR for example. In addition, some articles re-
ported the risk estimates by comparing categorical QoL
groups while others provided the risk estimates per 1 or
more units change in the continuous scale. Hence, the
different nature of each QoL scale and inconsistency in
risk comparison precluded us from including some arti-
cles in the meta-analyses. As such, only 11 studies were
included across the four meta-analyses of this systematic
review, and the meta-analyses still showed substantial
heterogeneity. Therefore, caution should be taken with
the interpretation of the overall effect estimates. More-
over, since the numbers of studies included in each
meta-analysis were fewer than 10 studies, the results
of funnel plots or Egger’s test should also be inter-
preted with caution. Of particular interest here, it has
commonly been reported that gender differences exist
in QoL and women of all age groups have lower QoL
than their male counterparts [86–90]. However, in
this review, it was not possible to perform statistical
pooling by gender and age groups due to the different
reporting strategies of the reviewed studies. Finally, it
is important to consider that although studies of mor-
tality are not directly affected by reverse causation,
individuals with severely declining health prior to
death, would likely report a decreased HRQoL. An
ideal study design would involve excluding individuals
who died in the first year of the study, or at least, to
run sensitivity analysis to ensure these early deaths
were not driving the results. Most of the studies in-
cluded in this review, did not undertake such ana-
lyses. Furthermore, around 10% of the included
studies have very short follow-up periods of less than
2 years.
Conclusion
This is the first systematic review and meta-analysis
that has determined whether QoL is associated with
mortality in the general non-patient population. In
summary, the findings provide evidence that better
QoL or HRQoL measured by different tools were as-
sociated with lower mortality risk in the general
population. Therefore, our findings could be applied
more generally to QoL or HRQoL assessed using dif-
ferent instruments. Our unique and first review indi-
cates that QoL measures can be considered as
potential screening tools beyond the existing trad-
itional clinical assessment of mortality risk. Addition-
ally, our result also encourages clinicians to
incorporate QoL measure into routine data collection
of health system which in turn could enable initiation
of early primary health care for people at high risk of
premature death. Furthermore, this study also adds
further support to the predictive capacity of physical
HRQoL for mortality risk. Additional research is
needed to determine whether these associations differ
across gender, and other populations in low- and
lower-middle-income countries, who have suffered of
a double burden of infectious and chronic diseases,
with having difficulties for accessing quality health
services. Ultimately these findings suggest the utility
of QoL measures to help identify populations at
greatest risk of mortality and who might benefit most
from routine screening in general practice and pos-
sible interventions.
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